Literature DB >> 30816505

MicroRNA‑144 suppresses aggressive phenotypes of tumor cells by targeting ANO1 in colorectal cancer.

Yasu Jiang1, Yunhui Cai2, Weiwei Shao2, Feng Li3, Zongyu Guan4, Yi Zhou4, Chong Tang1, Shichun Feng1.   

Abstract

The aim of the present study was to research the mechanism of action of microRNA‑144 (miR‑144) in colorectal cancer (CRC) and its role in tumor progression. It was demonstrated that miR‑144 was downregulated and anoctamin 1 (ANO1) expression was upregulated in CRC. The expression of ANO1 was negatively associated with that of miR‑144 in CRC. The present study indicated that upregulated expression of ANO1 was associated with poor differentiation and advanced tumor‑node‑metastasis stage. It was verified that upregulation of ANO1 expression activated the epidermal growth factor receptor/extracellular signal‑regulated kinase signaling pathway. It was also demonstrated that miR‑144 exerts strong tumor‑inhibiting effects by targeting ANO1. Therefore, miR‑144 may have potential as a prognostic marker or therapeutic target for CRC.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30816505     DOI: 10.3892/or.2019.7025

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  19 in total

Review 1.  Role of ANO1 in tumors and tumor immunity.

Authors:  Haini Li; Zongxue Yu; Haiyan Wang; Ning Wang; Xueguo Sun; Shengmei Yang; Xu Hua; Zongtao Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-26       Impact factor: 4.322

2.  DOG1 overexpression is associated with mismatch repair deficiency and BRAF mutations but unrelated to cancer progression in colorectal cancer.

Authors:  Kristina Jansen; Martina Kluth; Niclas C Blessin; Claudia Hube-Magg; Michael Neipp; Hamid Mofid; Hannes Lárusson; Thies Daniels; Christoph Isbert; Stephan Coerper; Daniel Ditterich; Holger Rupprecht; Albert Goetz; Christian Bernreuther; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Daniel Perez; Jakob R Izbicki; Frank Jacobsen; Till S Clauditz; Andreas H Marx; Till Krech
Journal:  Histol Histopathol       Date:  2022-06-01       Impact factor: 2.130

Review 3.  TMEM16A as a potential treatment target for head and neck cancer.

Authors:  Kohei Okuyama; Souichi Yanamoto
Journal:  J Exp Clin Cancer Res       Date:  2022-06-07

Review 4.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 5.  Role of ion channels in gastrointestinal cancer.

Authors:  Kyle J Anderson; Robert T Cormier; Patricia M Scott
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

Review 6.  MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers.

Authors:  Omid Kooshkaki; Zohre Rezaei; Meysam Rahmati; Parviz Vahedi; Afshin Derakhshani; Oronzo Brunetti; Amir Baghbanzadeh; Behzad Mansoori; Nicola Silvestris; Behzad Baradaran
Journal:  Int J Mol Sci       Date:  2020-04-08       Impact factor: 5.923

7.  MiR-506 Targets UHRF1 to Inhibit Colorectal Cancer Proliferation and Invasion via the KISS1/PI3K/NF-κB Signaling Axis.

Authors:  Yilin Lin; Zhihua Chen; Yan Zheng; Yisu Liu; Ji Gao; Suyong Lin; Shaoqin Chen
Journal:  Front Cell Dev Biol       Date:  2019-11-15

Review 8.  Calcium-Activated Chloride Channel ANO1/TMEM16A: Regulation of Expression and Signaling.

Authors:  Nickolai O Dulin
Journal:  Front Physiol       Date:  2020-11-05       Impact factor: 4.566

9.  miR-106a Targets Anoctamin 1 (ANO1) to Regulate Lipopolysaccharide (LPS)-Induced Inflammatory Response in Macrophages.

Authors:  Junfeng Heng; Dingye Wu; Shiqi Lu; Yiming Zhao
Journal:  Med Sci Monit       Date:  2020-10-10

Review 10.  The Ca2+-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases?

Authors:  Yani Liu; Zongtao Liu; KeWei Wang
Journal:  Acta Pharm Sin B       Date:  2020-12-09       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.